The Europe Single-use Bioprocessing Market would witness market growth of 15.5% CAGR during the forecast period (2022-2028).
Steel-based bioreactors and their parts are used in conventional bioprocessing and bioproduct production. The majority of these goods need sterilization and related equipment to produce contamination-free bioproducts, which raises the total expenditure required by manufacturers. However, because sterilization is not necessary with single-use bioprocessing devices, no further investments are required.
Compared to a stainless-steel facility of the same scale, the initial investment costs are comparatively lower. The direct cost savings in terms of low labor and material costs are one of the main benefits of single-use technology in pilot and full-scale manufacturing. When compared to comparable stainless-steel hardware systems, single-use systems (SUS) have lower direct labor costs during assembly as well as lower water and chemical costs.
Additionally, the use of single-use systems eliminates the need to clean-in-place (CIP) and sterilize-in-place (SIP), which increases facility utilization time and lowers operating expenses overall, particularly for raw materials.
The National Health Service (NHS) owns more than 98% of the UK's sixth-largest pharmaceutical sector, which is dominated by prescription drugs. It is a free market with significant participation from the majority of top international pharmaceutical businesses. Although the market's growth pace has slowed, it continues to be one of the areas of NHS spending that is expanding the fastest. The landscape of the pharmaceutical industry has recently undergone significant changes as a result of the creation of biological medications.
The Germany market dominated the Europe Single-use Bioprocessing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,733.8 million by 2028. The UK market is anticipated to grow at a CAGR of 14.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 16.4% during (2022 - 2028).
Based on Product, the market is segmented into Simple & Peripheral Elements (Tubing, Filters, Connectors, & Transfer Systems, Bags, Sampling Systems, Probes & Sensors [pH Sensor, Oxygen Sensor & Pressure Sensors, Temperature Sensors & Conductivity Sensors, Flow Sensors, and Others], and Others), Apparatus & Plants (Mixing, Storage, & Filling Systems, Bioreactors & Filtration System, Chromatography Systems & Pumps, and Others), and Work Equipment. Based on End-Use, the market is segmented into Biopharmaceutical Manufacturers and Academic & Clinical Research Institutes. Based on Workflow, the market is segmented into Upstream Bioprocessing, Fermentation, and Downstream Bioprocessing. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Single-use Bioprocessing Market will Hit $53.8 Billion by 2028, at a CAGR of 16%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Boehringer Ingelheim International GmbH, Corning Incorporated, Danaher Corporation, Eppendorf SE, Merck Millipore (Merck KGaA), Entegris, Inc., Sartorius Stedim Biotech S.A. (Sartorius AG), Thermo Fisher Scientific, Inc., and Avantor, Inc.
By Product
By End-use
By Workflow
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 